Luvometinib

芦沃美替尼

Report date: 2026/05/09 20:00:18
NME

Base Information

Drug NameLuvometinib
Drug Alias Name复迈替尼复迈宁FCN-159
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 1Dual specificity mitogen-activated protein kinase kinase 2
Therapy Area/IndicationsLow-grade GliomaSolid tumoursArteriovenous Malformations +[12] 
Global Approved IndicationsHistiocytosis, Langerhans-CellNeurofibromatosis 1Neurofibroma, Plexiform +[4] 
Approved Indications in ChinaHistiocytosis, Langerhans-CellNeurofibromatosis 1Neurofibroma, Plexiform +[4] 
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/27
Country/TerritoryUnited StatesPolandItaly +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesFochon Pharmaceuticals Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAsymchem Life Science (Tianjin) Co LtdFochon Pharmaceuticals LtdShanghai Fosun Pharmaceutical Industrial Development Co Ltd
Inactive CompaniesN/A
Active IndicationsLow-grade GliomaSolid tumoursArteriovenous Malformations +[11] 
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A